Inhibition of Human Osteosarcoma Cell Migration and Invasion by a Gene Silencer, Pyrrole-imidazole Polyamide, Targeted at the Human MMP9 NF-κB Binding Site
Overview
Authors
Affiliations
Osteosarcoma is one of the most prevalent bone tumors, occurring mostly in adolescence. However, no noticeable progress has been achieved in developing new therapeutic agents for this disease. Matrix metalloproteinase 9 (MMP9), a type IV collagenase, is a known anticancer target and is overexpressed in osteosarcomas. MMPs can degrade components of the extracellular matrix and are known to be involved in tumor invasion and metastasis. In the present study, we designed and synthesized a pyrrole-imidazole polyamide (HN.49), a gene-silencing agent that specifically targets the nuclear factor-kappa B (NF-κB) binding site of the human MMP9 promoter. We then examined the effect of HN.49 on the enzyme activity of MMP9 and the migration activity of osteosarcoma cells in vitro. It was clearly shown that HN.49 polyamide reduced the expression level of MMP9 mRNA and the enzymatic activity of MMP-9 in SaOS-2 cells. Moreover, HN.49 polyamide inhibited migration and invasion by SaOS-2 cells in in vitro wound-closure and matrigel-invasion assays. These results indicate that HN.49 may be a potential therapeutic agent for inhibiting the invasion and metastasis of osteosarcoma.
Alloisio G, Becerril Rodriguez D, Luce M, Ciaccio C, Marini S, Cricenti A Int J Mol Sci. 2023; 24(9).
PMID: 37175397 PMC: 10178551. DOI: 10.3390/ijms24097686.
The Road Not Taken with Pyrrole-Imidazole Polyamides: Off-Target Effects and Genomic Binding.
Lin J, Nagase H Biomolecules. 2020; 10(4).
PMID: 32260120 PMC: 7226143. DOI: 10.3390/biom10040544.
Kong L, Wu Z, Zhao Y, Lu X, Shi H, Liu S Biosci Rep. 2019; 39(6).
PMID: 31110076 PMC: 6549095. DOI: 10.1042/BSR20190850.
Targeting Transcription Factors for Cancer Treatment.
Lambert M, Jambon S, Depauw S, David-Cordonnier M Molecules. 2018; 23(6).
PMID: 29921764 PMC: 6100431. DOI: 10.3390/molecules23061479.
Hu X, Zhang C, Zhang Y, Hong C, Chen W, Shen W Oncotarget. 2017; 8(32):53210-53225.
PMID: 28881805 PMC: 5581104. DOI: 10.18632/oncotarget.18290.